|
1
|
Chen AY, Jemal A and Ward EM: Increasing
incidence of differentiated thyroid cancer in the United States,
1988-2005. Cancer. 115:3801–3807. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hay ID, Thompson GB, Grant CS, Bergstralh
EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL,
et al: Papillary thyroid carcinoma managed at the Mayo Clinic
during six decades (1940–1999): Temporal trends in initial therapy
and long-term outcome in 2444 consecutively treated patients. World
J Surg. 26:879–885. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burns WR and Zeiger MA: Differentiated
thyroid cancer. Semin Oncol. 37:557–566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xing M: Molecular pathogenesis and
mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nikiforov YE and Nikiforova MN: Molecular
genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol.
7:569–580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cancer Genome Atlas Research Network:
Integrated genomic characterization of papillary thyroid carcinoma.
Cell. 159:676–690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oikawa T and Yamada T: Molecular biology
of the Ets family of transcription factors. Gene. 303:11–34. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oliver JR, Kushwah R and Hu J: Multiple
roles of the epithelium-specific ETS transcription factor, ESE-1,
in development and disease. Lab Invest. 92:320–330. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Longoni N, Sarti M, Albino D, Civenni G,
Malek A, Ortelli E, Pinton S, Mello-Grand M, Ostano P, D'Ambrosio
G, et al: ETS transcription factor ESE1/ELF3 orchestrates a
positive feedback loop that constitutively activates NF-κB and
drives prostate cancer progression. Cancer Res. 73:4533–4547. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gajulapalli VN, Samanthapudi VS, Pulaganti
M, Khumukcham SS, Malisetty VL, Guruprasad L, Chitta SK and
Manavathi B: A transcriptional repressive role for
epithelial-specific ETS factor ELF3 on oestrogen receptor alpha in
breast cancer cells. Biochem J. 473:1047–1061. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cancer Genome Atlas Research Network.
Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA,
Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome
atlas pan-cancer analysis project. Nat Genet. 45:1113–1120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Haugen DR, Akslen LA, Varhaug JE and
Lillehaug JR: Expression of c-erbB-2 protein in papillary thyroid
carcinomas. Br J Cancer. 65:832–837. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Haugen DR, Akslen LA, Varhaug JE and
Lillehaug JR: Expression of c-erbB-3 and c-erbB-4 proteins in
papillary thyroid carcinomas. Cancer Res. 56:1184–1188.
1996.PubMed/NCBI
|
|
17
|
Mitsiades CS, Kotoula V, Poulaki V,
Sozopoulos E, Negri J, Charalambous E, Fanourakis G, Voutsinas G,
Tseleni-Balafouta S and Mitsiades N: Epidermal growth factor
receptor as a therapeutic target in human thyroid carcinoma:
Mutational and functional analysis. J Clin Endocrinol Metab.
91:3662–3666. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lemmon MA and Schlessinger J: Cell
signaling by receptor tyrosine kinases. Cell. 141:1117–1134. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang JL, Chen ZF, Chen HM, Wang MY, Kong
X, Wang YC, Sun TT, Hong J, Zou W, Xu J, et al: Elf3 drives
β-catenin transactivation and associates with poor prognosis in
colorectal cancer. Cell Death Dis. 5:e12632014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yeung TL, Leung CS, Wong KK,
Gutierrez-Hartmann A, Kwong J, Gershenson DM and Mok SC: ELF3 is a
negative regulator of epithelial-mesenchymal transition in ovarian
cancer cells. Oncotarget. 8:16951–16963. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gingras MC, Covington KR, Chang DK,
Donehower LA, Gill AJ, Ittmann MM, Creighton CJ, Johns AL, Shinbrot
E, Dewal N, et al: Ampullary cancers harbor ELF3 tumor suppressor
gene mutations and exhibit frequent WNT dysregulation. Cell Rep.
14:907–919. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yachida S, Wood LD, Suzuki M, Takai E,
Totoki Y, Kato M, Luchini C, Arai Y, Nakamura H, Hama N, et al:
Genomic sequencing identifies ELF3 as a driver of ampullary
carcinoma. Cancer Cell. 29:229–240. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
de Nigris F, Mega T, Berger N, Barone MV,
Santoro M, Viglietto G, Verde P and Fusco A: Induction of ETS-1 and
ETS-2 transcription factors is required for thyroid cell
transformation. Cancer Res. 61:2267–2275. 2001.PubMed/NCBI
|
|
24
|
Scott GK, Daniel JC, Xiong X, Maki RA,
Kabat D and Benz CC: Binding of an ETS-related protein within the
DNase I hypersensitive site of the HER2/neu promoter in human
breast cancer cells. J Biol Chem. 269:19848–19858. 1994.PubMed/NCBI
|
|
25
|
Chang CH, Scott GK, Kuo WL, Xiong X,
Suzdaltseva Y, Park JW, Sayre P, Erny K, Collins C, Gray JW, et al:
ESX: A structurally unique Ets overexpressed early during human
breast tumorigenesis. Oncogene. 14:1617–1622. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Eckel KL, Tentler JJ, Cappetta GJ, Diamond
SE and Gutierrez-Hartmann A: The epithelial-specific ETS
transcription factor ESX/ESE-1/Elf-3 modulates breast
cancer-associated gene expression. DNA Cell Biol. 22:79–94. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fisher KE, Jani JC, Fisher SB, Foulks C,
Hill CE, Weber CJ, Cohen C and Sharma J: Epidermal growth factor
receptor overexpression is a marker for adverse pathologic features
in papillary thyroid carcinoma. J Surg Res. 185:217–224. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Landriscina M, Pannone G, Piscazzi A, Toti
P, Fabiano A, Tortorella S, Occhini R, Ambrosi A, Bufo P and
Cignarelli M: Epidermal growth factor receptor 1 expression is
upregulated in undifferentiated thyroid carcinomas in humans.
Thyroid. 21:1227–1234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kolch W and Pitt A: Functional proteomics
to dissect tyrosine kinase signalling pathways in cancer. Nat Rev
Cancer. 10:618–629. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu J, Cho SN, Akkanti B, Jin N, Mao J,
Long W, Chen T, Zhang Y, Tang X, Wistub II, et al: ErbB2 pathway
activation upon Smad4 loss promotes lung tumor growth and
metastasis. Cell Rep. Mar 3–2015.(Epub ahead of print).
|
